Trial Profile

Prospective Randomized Evaluation of a new Formulation: Efficacy of Rotigotine

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 Feb 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rotigotine (Primary)
Indications Parkinson's disease
Focus Therapeutic Use
Acronyms PREFER

Most Recent Events

12 Feb 2016 Results of pooled post-hoc analysis of this and two other trials (see profile 26754 and 10814) published in the Clinical Neuropharmacology
20 Apr 2015 Post-hoc analysis on pooled data presented at the 67th Annual Meeting of the American Academy of Neurology (AAN), according to a UCB media release.
26 Apr 2012 Results presented at the 64th Annual Meeting of the American Academy of Neurology, according to a UCB media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com